tirzepatide approved for weight loss FDA Grants a New Indication Obesity Management GLP-1 Medications for Weight Loss:

The Next Frontier: CagriSema While Semaglutide is the current king, Novos future moat rests on CagriSema a fixed-dose combination of: Semaglutide (GLP-1): Lowers blood sugar and reduces appetite

Limited clinical data hinder confident conclusions despite positive findings in animal models

Overall, plant-based interventions may complement standard therapy and improve neuropsychiatric outcomes, though larger prospective studies are needed to clarify their efficacy and identify suitable patient subgroups

This article provides a balanced perspective on microdosing tirzepatide, including potential benefits, significant risks, and essential considerations

GLP-1 therapy should be combined with dietary modifications and physical activity as part of a comprehensive weight management programme under clinical supervision